Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SARTORIUS AG

(SRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius AG : No turn-around in sight

07/28/2021 | 02:32am EDT
long trade
Target price hit
Entry price : 499€ | Target : 570€ | Stop-loss : 450€ | Potential : 14.23%
Shares in Sartorius AG do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the € 570.
Sartorius AG : Sartorius AG : No turn-around in sight
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 79% by 2023.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses
  • With an expected P/E ratio at 87.4 and 79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 3 365 M 3 939 M 3 939 M
Net income 2021 422 M 494 M 494 M
Net Debt 2021 1 819 M 2 129 M 2 129 M
P/E ratio 2021 120x
Yield 2021 0,19%
Capitalization 42 475 M 49 859 M 49 721 M
EV / Sales 2021 13,2x
EV / Sales 2022 12,0x
Nbr of Employees 11 981
Free-Float 36,2%
Upcoming event on SARTORIUS AG
10/20/21
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 677,00 €
Average target price 382,92 €
Spread / Average Target -43,4%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chief Executive Officer
Rainer Lehmann Chief Financial Officer
Lothar Kappich Chairman-Supervisory Board
Oscar-Werner Reif Head-Research & Development
Volker Niebel Head-Production, Procurement & Business Operations
Sector and Competitors
1st jan.Capi. (M$)
SARTORIUS AG96.23%49 859
BIOTAGE AB (PUBL)85.90%1 940
REVENIO GROUP OYJ20.58%1 891
CELLAVISION AB (PUBL)45.02%1 223
VAREX IMAGING CORPORATION73.38%1 140
ANGLE PLC149.21%384